Bringing Breakthroughs to Life: Type 1 Diabetes Research Symposium

Join leading Canadian researchers, regulators, industry representatives, diabetes organizations and patients to foster dialogue, exchange knowledge and hear first-hand about new and emerging treatments for type 1 diabetes (T1D).

*Please note the event will be recorded.

VIEW EVENT RECORDINGS

VIEW AGENDA

LEARN MORE ABOUT OUR SPEAKERS

 

Event Recordings

Plenary:

 

Session 1:

 

Session 2:

 

Session 3

 

 

Agenda

Plenary (Zoom Webinar)

11:00 - 11:05

Opening Remarks

Dr. John Patrick Stewart

Director General,

Therapeutic Products Directorate

11:05 - 11:10

Opening Remarks

Dave Prowten

President & CEO,

JDRF Canada

11:10 - 11:40

Keynote #1

Dr. Norman Rosenblum

Director, CIHR-INMD:

100 years of insulin & the burden of diabetes in Canada

11:40 - 12:10

Keynote #2

Dr. Rémi Rabasa-Lhoret

IRCM, Université de Montréal, CHUM; Montréal: 

COVID-19 & type 1 diabète 

 

 

Session 1 (Interactive Zoom Meeting): Moving Beyond Insulin Therapy of Today

Chair: Dr. Sarah Linklater, Chief Scientific Officer, JDRF

12:15 - 12:35

Speaker

Dr. Bruce Perkins

University of Toronto:

Adjunctive-to-insulin therapies in type 1 diabetes

12:35 - 12:55

Speaker

Dr. Ahmad Haidar

McGill University, Montreal:

Advances in closed-loop therapy for type 1 diabetes

12:55 - 13:15

Speaker

Dr. Greg Korbutt

University of Alberta:

Advances in beta cell replacement: closing in on a functional cure for type 1 diabetes

13:15 - 13:35

Speaker

Dr. Bassam Haidar

English Slide Deck | French Slide Deck

 

Manager of the Metabolic and Musculoskeletal Drugs Division, Health Canada:

Advances in the treatment of severe hypoglycemia

13:35 - 13:55

All speakers

Panel discussion moderated by Dr. Sarah Linklater

13:55 - 14:00

Adjourn

Closing comments

 

 

Session 2 (Interactive Zoom Meeting): Device Innovation in T1D Management

Chair: Dr. Gayatri Jayaraman, Medical Devices Directorate, Health Canada

12:15 - 12:35

Speaker

Dr. Aaron Kowalski

CEO, JDRF International:

Device interoperability & patient choice

12:35 - 12:55

Speaker

Lane Desborough

CEO, Nudge BG, USA:

Towards the goal of fully automated insulin delivery

12:55 - 13:15

Speaker

Kate Farnsworth 

Why we loop: The T1D community perspective

13:15 - 13:35

Speaker

Marc Lamoureux

English Slide Deck | French Slide Deck

 

Manager, Health Canada

Grant Kealy,
Senior Scientific Evaluator; Medical Devices Directorate, Health Canada:                      

Medical Device Cybersecurity and Interdependent Devices

13:35 - 13:55

All speakers

Panel discussion moderated by Dr. Gayatri Jayaraman

13:55 - 14:00

Adjourn

Closing comments

 

 

Session 3 (Interactive Zoom Meeting): Immunotherapy & Biomarkers 

Chair: Dr. Agnes Klein, Senior Medical Advisor, Biologics and Radiopharmaceuticals Directorate, Health Canada

12:15 - 12:35

Speaker

Dr. Diane Wherrett

Hospital for Sick Children, University of Toronto: An update on teplizumab & other strategies being explored to prevent type 1 diabetes

12:35 - 12:55

Speaker

Dr. Bruce Verchere 

University of British Columbia:

Towards better biomarkers for type 1 diabetes risk, onset, and progression

12:55 - 13:15

Speaker

Dr. Peter Santamaria

University of Calgary: 

Advances in antigen-specific therapy for T1D

13:15 - 13:35

Speaker

Dr. Simon Sauvé

English Slide Deck | French Slide Deck

 

Center for Biologics Evaluation Health Canada, Ottawa, ON: 

Refuting Bad Science: Insulin Content of Products Marketed in Canada and Adaptability of Pharmacopeia Methods for Novel Product Regulation

13:35 - 13:55

All speakers

Panel discussion moderated by Dr. Agnes Klein

13:55 - 14:00

Adjourn

Closing comments

 

 

Speakers and Moderators

 


 

Lets turn type one into type none